FDA Signals New Testosterone Pathway - Takeaways - MDSpire

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

  • By

  • Kathryn Wighton

  • April 16, 2026

  • 2 min

Share

  • 1

    The FDA is encouraging sponsors of testosterone replacement therapy to pursue a new indication for low libido in men with idiopathic hypogonadism.

  • 2

    Currently, TRT products are approved only for men with hypogonadism due to established structural or genetic causes.

  • 3

    The FDA's review indicated that TRT may be safe and effective for men with decreased libido linked to idiopathic hypogonadism.

  • 4

    Sponsors are advised to contact the FDA by April 30 to discuss submission requirements for supplemental applications.

  • 5

    Any new indication approval will require substantial evidence of effectiveness and a favorable risk-benefit assessment.

Original Source(s)

FDA Signals New Testosterone Pathway

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

Telemedicine-Based Diabetes Management for Incarcerated Individuals